Obesity stocks were in focus today, with Eli Lilly (LLY) reporting a surprise Q3 earnings miss as sales for its blockbuster GLP-1 drugs fell short of estimates. While the miss largely seemed to be tied to inventory normalization, the pharma giant’s downwardly revised forecast pressured stocks involved in the booming weight-loss market. That includes San Diego-based Viking Therapeutics (VKTX), a pre-revenue clinical-stage biotech company that specializes in developing therapies for metabolic and endocrine disorders. Its portfolio includes promising treatments in various stages of development, w…